Skip to content

Kite doc survey: Bullish on Axi-Cel uptake

May 21, 2017

Jefferies analyst, Biren Amin, reiterated his Buy rating on shares of Kite Pharma (NASDAQ: KITE) after he conducted a proprietary survey on the NHL landscape for patients with aggressive NHL to gauge the outlook of KITE’s Axi-cel. Respondents were extremely bullish on uptake for 2018/2019, expecting 30%/40% of >2L pts to be tx’d with Axi-Cel.

For 2018 and 2019, the analyst models 5% and 12% in share driving sales of $183M and $666M, respectively, which are ahead of consensus. Overall, the analyst believes this survey reaffirms his bullish expectations for Axi-Cel’s launch.

No change to the price target of $101.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: